Client News

InflaRx Announces Participation in September Investor Conferences

Mallia Aesthetics Achieves Key Regulatory Steps for Novel sCD83-Derived Ingredient for Hair Growth

Nyxoah Reports Second Quarter Financial and Operating Results

Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®

Formycon Confirms Full-Year Guidance Following Business Development in line with Plan – Working Capital Raised

Newron Begins Enrollment in Pivotal Phase III ENIGMA-TRS Program with evenamide as Add-on Therapy in Patients with Treatment-Resistant Schizophrenia (TRS)

Nyxoah Announces Preliminary Results for the Second Quarter of 2025

NewronNotes the Publication of New Preclinical Research Suggesting Evenamide Ameliorates Schizophrenia-Related Dysfunction

Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea

InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update